The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists

Clay J. Cockerell, Jaime Tschen, Brent Evans, Emily Bess, John Kidd, Kathryn A. Kolquist, Colleen Rock, Loren E. Clarke

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

It is well documented that histopathologic examination is sometimes inadequate for accurate and reproducible diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature has been clinically validated as an adjunctive diagnostic test to differentiate benign nevi from malignant melanomas. This study aimed to quantify the impact of this test on diagnosis and treatment recommendations made by dermatopathologists. Diagnostically challenging melanocytic lesions encountered during routine dermatopathology practice were submitted for gene expression testing and received a melanoma diagnostic score (MDS). Submitting dermatopathologists completed a survey documenting pre-test diagnosis, level of diagnostic confidence, and recommendations for treatment. The survey was repeated after receiving the MDS. Changes between the pre- and post-test surveys were analyzed retrospectively. When the MDS was available as part of a comprehensive case evaluation in diagnostically challenging cases, definitive diagnoses were increased by 56.6% for cases that were initially indeterminate and changes in treatment recommendations occurred in 49.1% of cases. Treatment recommendations were changed to align with the test result in 76.6% of diagnostically challenging cases. The MDS impacts diagnosis and treatment recommendations by dermatopathologists confronted with diagnostically challenging melanocytic lesions. Increased data are needed in order to completely understand how use of the MDS will translate from dermatopathology to clinical practice.

Original languageEnglish (US)
Article numbere4887
JournalMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
Volume95
Issue number40
DOIs
StatePublished - 2016

Fingerprint

Transcriptome
Melanoma
Neoplasms
Nevi and Melanomas
Routine Diagnostic Tests
Gene Expression
Surveys and Questionnaires

Keywords

  • Clinical utility
  • Melanoma
  • Molecular diagnostic techniques
  • Nevi and melanomas

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists. / Cockerell, Clay J.; Tschen, Jaime; Evans, Brent; Bess, Emily; Kidd, John; Kolquist, Kathryn A.; Rock, Colleen; Clarke, Loren E.

In: Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, Vol. 95, No. 40, e4887, 2016.

Research output: Contribution to journalArticle

Cockerell, Clay J. ; Tschen, Jaime ; Evans, Brent ; Bess, Emily ; Kidd, John ; Kolquist, Kathryn A. ; Rock, Colleen ; Clarke, Loren E. / The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists. In: Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries. 2016 ; Vol. 95, No. 40.
@article{d693e173a05d43c2b54ea2d4168c3716,
title = "The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists",
abstract = "It is well documented that histopathologic examination is sometimes inadequate for accurate and reproducible diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature has been clinically validated as an adjunctive diagnostic test to differentiate benign nevi from malignant melanomas. This study aimed to quantify the impact of this test on diagnosis and treatment recommendations made by dermatopathologists. Diagnostically challenging melanocytic lesions encountered during routine dermatopathology practice were submitted for gene expression testing and received a melanoma diagnostic score (MDS). Submitting dermatopathologists completed a survey documenting pre-test diagnosis, level of diagnostic confidence, and recommendations for treatment. The survey was repeated after receiving the MDS. Changes between the pre- and post-test surveys were analyzed retrospectively. When the MDS was available as part of a comprehensive case evaluation in diagnostically challenging cases, definitive diagnoses were increased by 56.6{\%} for cases that were initially indeterminate and changes in treatment recommendations occurred in 49.1{\%} of cases. Treatment recommendations were changed to align with the test result in 76.6{\%} of diagnostically challenging cases. The MDS impacts diagnosis and treatment recommendations by dermatopathologists confronted with diagnostically challenging melanocytic lesions. Increased data are needed in order to completely understand how use of the MDS will translate from dermatopathology to clinical practice.",
keywords = "Clinical utility, Melanoma, Molecular diagnostic techniques, Nevi and melanomas",
author = "Cockerell, {Clay J.} and Jaime Tschen and Brent Evans and Emily Bess and John Kidd and Kolquist, {Kathryn A.} and Colleen Rock and Clarke, {Loren E.}",
year = "2016",
doi = "10.1097/MD.0000000000004887",
language = "English (US)",
volume = "95",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "40",

}

TY - JOUR

T1 - The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists

AU - Cockerell, Clay J.

AU - Tschen, Jaime

AU - Evans, Brent

AU - Bess, Emily

AU - Kidd, John

AU - Kolquist, Kathryn A.

AU - Rock, Colleen

AU - Clarke, Loren E.

PY - 2016

Y1 - 2016

N2 - It is well documented that histopathologic examination is sometimes inadequate for accurate and reproducible diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature has been clinically validated as an adjunctive diagnostic test to differentiate benign nevi from malignant melanomas. This study aimed to quantify the impact of this test on diagnosis and treatment recommendations made by dermatopathologists. Diagnostically challenging melanocytic lesions encountered during routine dermatopathology practice were submitted for gene expression testing and received a melanoma diagnostic score (MDS). Submitting dermatopathologists completed a survey documenting pre-test diagnosis, level of diagnostic confidence, and recommendations for treatment. The survey was repeated after receiving the MDS. Changes between the pre- and post-test surveys were analyzed retrospectively. When the MDS was available as part of a comprehensive case evaluation in diagnostically challenging cases, definitive diagnoses were increased by 56.6% for cases that were initially indeterminate and changes in treatment recommendations occurred in 49.1% of cases. Treatment recommendations were changed to align with the test result in 76.6% of diagnostically challenging cases. The MDS impacts diagnosis and treatment recommendations by dermatopathologists confronted with diagnostically challenging melanocytic lesions. Increased data are needed in order to completely understand how use of the MDS will translate from dermatopathology to clinical practice.

AB - It is well documented that histopathologic examination is sometimes inadequate for accurate and reproducible diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature has been clinically validated as an adjunctive diagnostic test to differentiate benign nevi from malignant melanomas. This study aimed to quantify the impact of this test on diagnosis and treatment recommendations made by dermatopathologists. Diagnostically challenging melanocytic lesions encountered during routine dermatopathology practice were submitted for gene expression testing and received a melanoma diagnostic score (MDS). Submitting dermatopathologists completed a survey documenting pre-test diagnosis, level of diagnostic confidence, and recommendations for treatment. The survey was repeated after receiving the MDS. Changes between the pre- and post-test surveys were analyzed retrospectively. When the MDS was available as part of a comprehensive case evaluation in diagnostically challenging cases, definitive diagnoses were increased by 56.6% for cases that were initially indeterminate and changes in treatment recommendations occurred in 49.1% of cases. Treatment recommendations were changed to align with the test result in 76.6% of diagnostically challenging cases. The MDS impacts diagnosis and treatment recommendations by dermatopathologists confronted with diagnostically challenging melanocytic lesions. Increased data are needed in order to completely understand how use of the MDS will translate from dermatopathology to clinical practice.

KW - Clinical utility

KW - Melanoma

KW - Molecular diagnostic techniques

KW - Nevi and melanomas

UR - http://www.scopus.com/inward/record.url?scp=84995561939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995561939&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000004887

DO - 10.1097/MD.0000000000004887

M3 - Article

C2 - 27749545

AN - SCOPUS:84995561939

VL - 95

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 40

M1 - e4887

ER -